Auro Laboratories Ltd vs Novartis India Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Auro Laboratories Ltd is ₹ 249.05 as of 05 May 15:30 . The P/E Ratio of Auro Laboratories Ltd changed from 7 on March 2021 to 78.2 on March 2025 . This represents a CAGR of 62.04% over 5 yearsThe P/E Ratio of Novartis India Ltd changed from 65.2 on March 2021 to 19.2 on March 2025 . This represents a CAGR of -21.69% over 5 years The Market Cap of Auro Laboratories Ltd changed from ₹ 50.55 crore on March 2021 to ₹ 143.69 crore on March 2025 . This represents a CAGR of 23.24% over 5 yearsThe Market Cap of Novartis India Ltd changed from ₹ 1362 crore on March 2021 to ₹ 1938 crore on March 2025 . This represents a CAGR of 7.30% over 5 years The revenue of Auro Laboratories Ltd for the Sep '25 is ₹ 9.81 crore as compare to the Jun '25 revenue of ₹ 3.19 crore. This represent the growth of 207.52% The revenue of Novartis India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Auro Laboratories Ltd for the Sep '25 is ₹ 3.33 crore as compare to the Jun '25 ebitda of ₹ 0.45 crore. This represent the growth of 640% The ebitda of Novartis India Ltd for the Sep '25 is ₹ 0 crore as compare to the Jun '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Auro Laboratories Ltd changed from ₹ 0.75 crore to ₹ 0.72 crore over 4 quarters. This represents a CAGR of -4.00% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 4 quarters. This represents a CAGR of 0.0% The Dividend Payout of Auro Laboratories Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 years .

About Auro Laboratories Ltd

Auro Laboratories Limited, founded in 1992, has been manufacturing and providing generic Active Pharmaceutical Ingredients (API).
Currently, the Company is specializing in producing Anti Diabetics like Metformin HCL. It is the first-line treatment for type 2 diabetes.
The Company is headquartered in Mumbai and it has manufacturing facility at Palghar in Maharashtra.
The facility has all the required certifications from Indian authorities and European registration organization Since inception, the Company focused on providing quality pharmaceuticals while maintaining high manufacturing standards.
Company presently has 1800 MTPA of Metformin HCL manufacturing capacity, with projects underway to expand the capacity to 3600 MTPA. The Company's primary focus was on Anti-Diabetic Drugs, which estimated to be one of the fastest growing therapeutic segments.

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

FAQs for the comparison of Auro Laboratories Ltd and Novartis India Ltd

Which company has a larger market capitalization, Auro Laboratories Ltd or Novartis India Ltd?

Market cap of Auro Laboratories Ltd is 155 Cr while Market cap of Novartis India Ltd is 2,563 Cr

What are the key factors driving the stock performance of Auro Laboratories Ltd and Novartis India Ltd?

The stock performance of Auro Laboratories Ltd and Novartis India Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Auro Laboratories Ltd and Novartis India Ltd?

As of May 5, 2026, the Auro Laboratories Ltd stock price is INR ₹249.05. On the other hand, Novartis India Ltd stock price is INR ₹1038.1.

How do dividend payouts of Auro Laboratories Ltd and Novartis India Ltd compare?

To compare the dividend payouts of Auro Laboratories Ltd and Novartis India Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.